GlobeNewswire

Ballast Point® Releases Aloha Sculpin® IPA Nationwide

Dela

Brewery uses 'Brux Trois' yeast; turns award-winning flagship beer into tropical oasis

SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- By using a newly developed Belgian yeast strain in an award-winning IPA, Ballast Point continues to showcase its innovative spirit with Aloha Sculpin, the latest addition to the Sculpin IPA family - now available nationwide.

Aloha Sculpin IPA features a distinct yeast strain known as Saccharomyces "Bruxellensis" Trois, or Brux Trois, turning the flagship IPA into a tropical oasis with aromas and flavors of guava, mango, and pineapple without any fruit additions. While Belgian yeast strains are known for their clove and banana-like aroma, this strain bears exotic fruit aromas. It also adds a slight haze to the beer, creating a smooth mouthfeel to round out its juicy character.

Not only does this yeast strain add a unique flavor profile to the brew, but its use in Aloha Sculpin marks the first time an IPA brewed with Saccharomyces brux Trois is being packaged and made available nationwide.

"We're always experimenting with new ingredients and methods," said James Murray, vice president of brewing at Ballast Point. "Most brewers tend to experiment with hops for flavor and aroma. But when we tasted the guava, mango and pineapple notes from this yeast in other R&D recipes we brewed, we knew it would really enhance the bright, tropical fruit characteristics already present in Sculpin IPA."

Innovation is a part of Ballast Point's DNA and has been a critical part of the brewery's success dating back to the days of Home Brew Mart. As a pioneer in the San Diego craft beer movement, the brewery currently makes over 50 styles of beer, each with innovation and quality in mind. Experimenting with Brux Trois yeast is a testament to this focus.

"This strain is a bit finicky," said Lauren Zeidler, director of quality at Ballast Point. "It's very particular about what it likes and doesn't, so we had to get to know its preferences and adjust accordingly. It was a unique challenge, but it made the brewing and batch scaling even more of a satisfying accomplishment."

The original Sculpin IPA launched in 2005 and has since become the hallmark of the west coast-style IPA, winning gold medals at the World Beer Cup (2010, 2014) and European Beer Star (2010, 2011). Years later, the Sculpin family has expanded to include Grapefruit, Pineapple, Habanero, Unfiltered - and now Aloha Sculpin.

Aloha Sculpin IPA is a spring/summer seasonal release under Ballast Point's flagship tier and is now rolling out nationwide in both draft and six-pack bottles.

For more information, visit www.BallastPoint.com.

About Ballast Point Brewing Company
Started in 1996 by a small group of home brewers in San Diego, Ballast Point has a 20-plus-year history of supporting the art of home brewing and developing high-quality, innovative and award-winning beer. Ballast Point has become one of the nation's leading craft breweries by exploring new tastes and techniques to create the perfect balance of taste and aroma. At Ballast Point, a culture of quality persists from selection of raw materials to the brewing process to the finished product and beyond. From developing a proprietary yeast for our amber ale to creating a breakthrough gold medal-winning IPA, Ballast Point is dedicated to the craft of brewing beers for all to enjoy.

Media Contact:
Jennifer Dohm
312-741-2089
Jennifer.dohm@cbrands.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/35145537-1f86-4c08-9b33-453b9a5a96f8




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ballast Point Brewing Company via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum